260 related articles for article (PubMed ID: 36395737)
1. Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A multicentre study.
She Y; He B; Wang F; Zhong Y; Wang T; Liu Z; Yang M; Yu B; Deng J; Sun X; Wu C; Hou L; Zhu Y; Yang Y; Hu H; Dong D; Chen C; Tian J
EBioMedicine; 2022 Dec; 86():104364. PubMed ID: 36395737
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive prediction for pathologic complete response to neoadjuvant chemoimmunotherapy in lung cancer using CT-based deep learning: a multicenter study.
Qu W; Chen C; Cai C; Gong M; Luo Q; Song Y; Yang M; Shi M
Front Immunol; 2024; 15():1327779. PubMed ID: 38596674
[TBL] [Abstract][Full Text] [Related]
3. Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
Han X; Wang M; Zheng Y; Wang N; Wu Y; Ding C; Jia X; Yang R; Geng M; Chen Z; Zhang S; Zhang K; Li Y; Liu J; Gu J; Liao Y; Fan J; Shi H
Eur Radiol; 2024 Apr; 34(4):2716-2726. PubMed ID: 37736804
[TBL] [Abstract][Full Text] [Related]
4. The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study.
Li C; Wu J; Jiang L; Zhang L; Huang J; Tian Y; Zhao Y; Liu X; Xia L; E H; Gao P; Hou L; Yang M; Ma M; Su C; Zhang H; Chen H; She Y; Xie D; Luo Q; Chen C
Cancer Immunol Immunother; 2023 Mar; 72(3):783-794. PubMed ID: 36056951
[TBL] [Abstract][Full Text] [Related]
5. [
Yang M; Li X; Cai C; Liu C; Ma M; Qu W; Zhong S; Zheng E; Zhu H; Jin F; Shi H
Eur Radiol; 2023 Dec; ():. PubMed ID: 38127071
[TBL] [Abstract][Full Text] [Related]
6. Utility of
Zhuang F; Haoran E; Huang J; Wu J; Xu L; Zhang L; Li Q; Li C; Zhao Y; Yang M; Ma M; She Y; Chen H; Luo Q; Zhao D; Chen C
Lung Cancer; 2023 Apr; 178():20-27. PubMed ID: 36764154
[TBL] [Abstract][Full Text] [Related]
7. A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy.
Wang F; Yang H; Chen W; Ruan L; Jiang T; Cheng L; Jiang H; Fang M
Curr Probl Cancer; 2024 May; 50():101098. PubMed ID: 38704949
[TBL] [Abstract][Full Text] [Related]
8. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
[TBL] [Abstract][Full Text] [Related]
9. Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non-small-cell lung cancer.
Han R; Zhang Y; Wang T; Xiao H; Luo Z; Shen C; Li J; Zhao C; Li L; Zhu M; Du H; Tang H; Ma Z; Wang Y; He Y
Cancer Sci; 2023 Jun; 114(6):2569-2583. PubMed ID: 36880750
[TBL] [Abstract][Full Text] [Related]
10. Comparison of different criteria for estimating major pathological response in resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
Sun W; Liu X; Wang C; Jiang Y; Lin D
Ann Diagn Pathol; 2024 Apr; 69():152268. PubMed ID: 38301396
[TBL] [Abstract][Full Text] [Related]
11. Early prediction of treatment response to neoadjuvant chemotherapy based on longitudinal ultrasound images of HER2-positive breast cancer patients by Siamese multi-task network: A multicentre, retrospective cohort study.
Liu Y; Wang Y; Wang Y; Xie Y; Cui Y; Feng S; Yao M; Qiu B; Shen W; Chen D; Du G; Chen X; Liu Z; Li Z; Yang X; Liang C; Wu L
EClinicalMedicine; 2022 Oct; 52():101562. PubMed ID: 35928032
[TBL] [Abstract][Full Text] [Related]
12. Easily applicable predictive score for MPR based on parameters before neoadjuvant chemoimmunotherapy in operable NSCLC: a single-center, ambispective, observational study.
Hu M; Li X; Lin H; Lu B; Wang Q; Tong L; Li H; Che N; Hung S; Han Y; Shi K; Li C; Zhang H; Liu Z; Zhang T
Int J Surg; 2024 Apr; 110(4):2275-2287. PubMed ID: 38265431
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study.
Feng L; Liu Z; Li C; Li Z; Lou X; Shao L; Wang Y; Huang Y; Chen H; Pang X; Liu S; He F; Zheng J; Meng X; Xie P; Yang G; Ding Y; Wei M; Yun J; Hung MC; Zhou W; Wahl DR; Lan P; Tian J; Wan X
Lancet Digit Health; 2022 Jan; 4(1):e8-e17. PubMed ID: 34952679
[TBL] [Abstract][Full Text] [Related]
14. Deep Learning for Predicting Effect of Neoadjuvant Therapies in Non-Small Cell Lung Carcinomas With Histologic Images.
Terada K; Yoshizawa A; Liu X; Ito H; Hamaji M; Menju T; Date H; Bise R; Haga H
Mod Pathol; 2023 Nov; 36(11):100302. PubMed ID: 37580019
[TBL] [Abstract][Full Text] [Related]
15. Deep radiomics-based fusion model for prediction of bevacizumab treatment response and outcome in patients with colorectal cancer liver metastases: a multicentre cohort study.
Zhou S; Sun D; Mao W; Liu Y; Cen W; Ye L; Liang F; Xu J; Shi H; Ji Y; Wang L; Chang W
EClinicalMedicine; 2023 Nov; 65():102271. PubMed ID: 37869523
[TBL] [Abstract][Full Text] [Related]
16. Automated and reusable deep learning (AutoRDL) framework for predicting response to neoadjuvant chemotherapy and axillary lymph node metastasis in breast cancer using ultrasound images: a retrospective, multicentre study.
You J; Huang Y; Ouyang L; Zhang X; Chen P; Wu X; Jin Z; Shen H; Zhang L; Chen Q; Pei S; Zhang B; Zhang S
EClinicalMedicine; 2024 Mar; 69():102499. PubMed ID: 38440400
[TBL] [Abstract][Full Text] [Related]
17. Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB-III non-small cell lung cancer patients using radiomic features.
Yang N; Yue HL; Zhang BH; Chen J; Chu Q; Wang JX; Yu XP; Jian L; Bin YW; Liu SY; Liu J; Zeng L; Yang HY; Zhou CH; Jiang WJ; Liu L; Zhang YC; Xiong Y; Wang Z
Thorac Cancer; 2023 Oct; 14(28):2869-2876. PubMed ID: 37596822
[TBL] [Abstract][Full Text] [Related]
18. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images.
Tian P; He B; Mu W; Liu K; Liu L; Zeng H; Liu Y; Jiang L; Zhou P; Huang Z; Dong D; Li W
Theranostics; 2021; 11(5):2098-2107. PubMed ID: 33500713
[No Abstract] [Full Text] [Related]
19. Ct-based subregional radiomics using hand-crafted and deep learning features for prediction of therapeutic response to anti-PD1 therapy in NSCLC.
Hu Y; Jiang T; Wang H; Song J; Yang Z; Wang Y; Su J; Jin M; Chang S; Deng K; Jiang W
Phys Med; 2024 Jan; 117():103200. PubMed ID: 38160516
[TBL] [Abstract][Full Text] [Related]
20. Radiographical assessment of tumour stroma and treatment outcomes using deep learning: a retrospective, multicohort study.
Jiang Y; Liang X; Han Z; Wang W; Xi S; Li T; Chen C; Yuan Q; Li N; Yu J; Xie Y; Xu Y; Zhou Z; Poultsides GA; Li G; Li R
Lancet Digit Health; 2021 Jun; 3(6):e371-e382. PubMed ID: 34045003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
